Literature DB >> 24213532

Tumor suppressor SCUBE2 inhibits breast-cancer cell migration and invasion through the reversal of epithelial-mesenchymal transition.

Yuh-Charn Lin1, Yi-Ching Lee, Ling-Hui Li, Chien-Jui Cheng, Ruey-Bing Yang.   

Abstract

Signal peptide-CUB-EGF domain-containing protein 2 (SCUBE2) belongs to a secreted and membrane-associated multi-domain SCUBE protein family. We previously demonstrated that SCUBE2 is a novel breast-tumor suppressor and could be a useful prognostic marker. However, the role of SCUBE2 in breast-cancer cell migration and invasion and how it is regulated during the epithelial-mesenchymal transition (EMT) remain undefined. In this study, we showed that ectopic SCUBE2 overexpression could enhance the formation of E-cadherin-containing adherens junctions by β-catenin-SOX-mediated induction of forkhead box A1 (a positive regulator of E-cadherin) and upregulation of E-cadherin, which in turn led to epithelial transition and inhibited migration and invasion of aggressive MDA-MB-231 breast-carcinoma cells. SCUBE2 expression was repressed together with that of E-cadherin in TGF-β-induced EMT; direct expression of SCUBE2 alone was sufficient to inhibit the TGF-β-induced EMT. Furthermore, quantitative DNA methylation, methylation-specific PCR, and chromatin immunoprecipitation analyses revealed that SCUBE2 expression was inactivated by DNA hypermethylation at the CpG islands by recruiting and binding DNA methyltransferase 1 during TGF-β-induced EMT. Together, our results suggest that SCUBE2 plays a key role in suppressing breast-carcinoma-cell mobility and invasiveness by increasing the formation of the epithelial E-cadherin-containing adherens junctions to promote epithelial differentiation and drive the reversal of EMT.

Entities:  

Keywords:  Breast cancer; DNA hypermethylation; DNA methyltransferase; Epigenetic regulation; Epithelial–mesenchymal transition; Tumor suppressor

Mesh:

Substances:

Year:  2013        PMID: 24213532     DOI: 10.1242/jcs.132779

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  19 in total

1.  SMYD5 Controls Heterochromatin and Chromosome Integrity during Embryonic Stem Cell Differentiation.

Authors:  Benjamin L Kidder; Runsheng He; Darawalee Wangsa; Hesed M Padilla-Nash; M Margarida Bernardo; Shijie Sheng; Thomas Ried; Keji Zhao
Journal:  Cancer Res       Date:  2017-09-26       Impact factor: 12.701

2.  Metformin mediated reversal of epithelial to mesenchymal transition is triggered by epigenetic changes in E-cadherin promoter.

Authors:  Poulomi Banerjee; Harshini Surendran; Debabani Roy Chowdhury; Karthik Prabhakar; Rajarshi Pal
Journal:  J Mol Med (Berl)       Date:  2016-08-17       Impact factor: 4.599

3.  MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients.

Authors:  Josien C Haan; Rajith Bhaskaran; Architha Ellappalayam; Yannick Bijl; Christian J Griffioen; Ersan Lujinovic; William M Audeh; Frédérique Penault-Llorca; Lorenza Mittempergher; Annuska M Glas
Journal:  Genes Chromosomes Cancer       Date:  2021-12-11       Impact factor: 4.263

4.  Secreted frizzled-related protein 4 inhibits glioma stem-like cells by reversing epithelial to mesenchymal transition, inducing apoptosis and decreasing cancer stem cell properties.

Authors:  G Bhuvanalakshmi; Frank Arfuso; Michael Millward; Arun Dharmarajan; Sudha Warrier
Journal:  PLoS One       Date:  2015-06-01       Impact factor: 3.240

5.  MicroRNA-93 Promotes Epithelial-Mesenchymal Transition of Endometrial Carcinoma Cells.

Authors:  Shuo Chen; Xi Chen; Kai-Xuan Sun; Yin-Ling Xiu; Bo-Liang Liu; Miao-Xiao Feng; Xiu-Bo Sang; Yang Zhao
Journal:  PLoS One       Date:  2016-11-09       Impact factor: 3.240

Review 6.  Mechanisms of TGFβ-Induced Epithelial-Mesenchymal Transition.

Authors:  Aristidis Moustakas; Carl-Henrik Heldin
Journal:  J Clin Med       Date:  2016-06-29       Impact factor: 4.241

7.  TMEM196 acts as a novel functional tumour suppressor inactivated by DNA methylation and is a potential prognostic biomarker in lung cancer.

Authors:  Wen-bin Liu; Fei Han; Xiao Jiang; Hong-qiang Chen; Huan Zhao; Yong Liu; Yong-hong Li; Chuanshu Huang; Jia Cao; Jin-yi Liu
Journal:  Oncotarget       Date:  2015-08-28

8.  Eupatolide inhibits the TGF-β1-induced migration of breast cancer cells via downregulation of SMAD3 phosphorylation and transcriptional repression of ALK5.

Authors:  Ariundavaa Boldbaatar; Sunyi Lee; Sora Han; Ae Lee Jeong; Hye In Ka; Sumiyasuren Buyanravjikh; Jeong Hyung Lee; Jong-Seok Lim; Myung Sok Lee; Young Yang
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

9.  Enhanced expression of histone chaperone APLF associate with breast cancer.

Authors:  Aditi Majumder; Khaja Moheiddin Syed; Ananda Mukherjee; Manendra Babu Lankadasari; Juberiya Mohammed Azeez; Sreeharshan Sreeja; Kuzhuvelil B Harikumar; Madhavan Radhakrishna Pillai; Debasree Dutta
Journal:  Mol Cancer       Date:  2018-03-26       Impact factor: 27.401

10.  The footprint of the ageing stroma in older patients with breast cancer.

Authors:  Barbara Brouwers; Debora Fumagalli; Sylvain Brohee; Sigrid Hatse; Olivier Govaere; Giuseppe Floris; Kathleen Van den Eynde; Yacine Bareche; Patrick Schöffski; Ann Smeets; Patrick Neven; Diether Lambrechts; Christos Sotiriou; Hans Wildiers
Journal:  Breast Cancer Res       Date:  2017-07-03       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.